BIOGEN INC (IDP.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
IDP.DE Key Statistics, Chart & Performance
The current stock price of IDP.DE is 153.55 EUR. In the past month the price increased by 17.12%. In the past year, price increased by 2.23%.
IDP.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 74.67 | 49.19B | ||
| 1AE.DE | ARGENX SE | 72.95 | 48.06B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.07B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.53B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.89B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.78B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| 5CV.DE | CUREVAC NV | 5.05 | 989.85M | ||
| NANO.PA | NANOBIOTIX | N/A | 852.45M | ||
| 6IV.DE | INVENTIVA SA | N/A | 713.45M | ||
| IVA.PA | INVENTIVA SA | N/A | 659.97M | ||
| PHIL.MI | PHILOGEN SPA | 20.18 | 672.52M |
Related stock screener links
About IDP.DE
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Company Info
BIOGEN INC
225 Binney Street
Cambridge MASSACHUSETTS US
Employees: 7605
Phone: 17814642000
BIOGEN INC / IDP.DE FAQ
What does BIOGEN INC do?
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Can you provide the latest stock price for BIOGEN INC?
The current stock price of IDP.DE is 153.55 EUR. The price increased by 0.49% in the last trading session.
Does IDP stock pay dividends?
IDP.DE does not pay a dividend.
What is the ChartMill rating of BIOGEN INC stock?
IDP.DE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Where is BIOGEN INC (IDP.DE) stock traded?
IDP.DE stock is listed on the Frankfurt Stock Exchange exchange.
Is BIOGEN INC (IDP.DE) expected to grow?
The Revenue of BIOGEN INC (IDP.DE) is expected to grow by 1.35% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for IDP stock?
BIOGEN INC (IDP.DE) currently has 7605 employees.
IDP.DE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IDP.DE. When comparing the yearly performance of all stocks, IDP.DE is one of the better performing stocks in the market, outperforming 81.71% of all stocks.
IDP.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE. IDP.DE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
IDP.DE Financial Highlights
Over the last trailing twelve months IDP.DE reported a non-GAAP Earnings per Share(EPS) of 14.41. The EPS increased by 2.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.98% | ||
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| Debt/Equity | 0.35 |
IDP.DE Forecast & Estimates
42 analysts have analysed IDP.DE and the average price target is 154.93 EUR. This implies a price increase of 0.9% is expected in the next year compared to the current price of 153.55.
For the next year, analysts expect an EPS growth of -5.79% and a revenue growth 1.35% for IDP.DE